[1]谢孟欣 梁红生.单片复方制剂在原发性高血压治疗中的研究进展[J].心血管病学进展,2022,(12):1096.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.009]
　XIE Mengxin,LIANG Hongsheng.Single-Pill Combination in Essential Hypertension[J].Advances in Cardiovascular Diseases,2022,(12):1096.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.009]
点击复制

单片复方制剂在原发性高血压治疗中的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年12期
页码:
1096
栏目:
综述
出版日期:
2022-12-25

文章信息/Info

Title:
Single-Pill Combination in Essential Hypertension
作者:
谢孟欣1 梁红生2
(1.广东医科大学,广东 湛江 524000;2.广东医科大学附属东莞市第八人民医院心血管内科,广东 东莞 523320)
Author(s):
XIE Mengxin1; LIANG Hongsheng2
(1.Guangdong Medical University,Zhanjiang 524000,Guangdong,China;2.Department of Cardiology,Dongguan Eighth People’s Hospital Affiliated to Guangdong Medical University,Dongguan 523 320,Guangdong,China)
关键词:
原发性高血压; 单片复方制剂; 控制率; 依从性
Keywords:
Essential hypertension; Single-pill combination; Controlrate; Adherence
DOI:
10.16806/j.cnki.issn.1004-3934.2022.12.009
摘要:
原发性高血压是全球公共卫生问题，是导致心脑血管疾病发生和死亡的最主要的危险因素。高血压会显著增加脑卒中、心肌梗死、心力衰竭及慢性肾病等并发症的发生率和死亡率，严重危害人体健康。因此，预防和治疗高血压对减轻全球疾病负担，延长人类寿命有重要意义。目前，中国原发性高血压的患病率呈上升趋势，但血压控制率仍很低。随着医疗科技的发展，在降压方案选择方面，单片复方制剂（SPC）在治疗原发性高血压方面是一个热点话题。现通过整理近年来最新发表的研究，旨在进一步分析讨论SPC治疗原发性高血压的疗效，并为临床医生在降压方案选择方面提供参考。
Abstract:
Essential hypertension is a global public health problem and the main risk factor leading to the occurrence and death of cardiovascular and cerebrovascular diseases. Hypertension can significantly increase the incidence and death rate of complications such as stroke ,myocardial infarction,heart failure,and chronic kidney disease and seriously endanger human health. Therefore,the prevention and treatment of hypertension are of great significance in reducing the global burden of disease and prolonging human life. The prevalence of hypertension in China is on the rise,but the blood pressure control rate is still very low. With the development of medical science and technology,single-pill combination (SPC) is a hot topic in treating essential hypertension in terms of antihypertensive regimen selection. This article aims to analyze further and discuss the efficacy of SPC preparation in treating essential hypertension by sorting out the latest published studies in recent years ,and provide reference for clinicians in the selection of antihypertensive programs.

参考文献/References:

[1].林果为,王吉耀,葛均波. 实用内科学(第15版)[M]. 北京:人民卫生出版社,2017:997-1016.
[2].Wang Z,Chen Z,Zhang L,et al. Status of hypertension in China:results from the China hypertension survey,2012—2015[J]. Circulation,2018,137(22):2344-2356.
[3].Yoon SS,Gu Q,Nwankwo T,et al. Trends in blood pressure among adults with hypertension:United States,2003—2012[J]. Hypertension,2015,65(1):54-61.
[4].Thomopoulos C,Parati G,Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1.Overview,meta-analyses,and meta-regression analyses of randomized trials[J]. J Hypertens,2014,32(12):2285-2295.
[5].Law MR,Morris JK,Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease:meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies[J]. BMJ,2009,338:b1665.
[6].国家心血管病中心国家基本公共卫生服务项目基层高血压管理办公室,国家基层高血压管理专家委员会. 国家基层高血压防治管理指南2020版[J]. 中国循环杂志,2021,36(3):209-220.
[7].中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等. 中国高血压防治指南( 2018年修订版)[J]. 中国心血管杂志,2019,24(1):24-56.
[8].Du LP,Cheng ZW,Zhang YX,et al. The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension:a meta-analysis[J]. J Clin Hypertens (Greenwich),2018,20(5):902-907.
[9].Williams B,Mancia G,Spiering W,et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension[J]. Eur Heart J ,2018,39(33):3021-3104.
[10].中国老年医学学会高血压分会,中华医学会心血管病学分会,中国医师协会高血压专业委员会,等. 复方利血平氨苯蝶啶片(O号?)临床应用中国专家共识(2021版)[J]. 中华老年多器官疾病杂志,2021,20(9):641-645.
[11].胡允彩. 复方利血平氨苯蝶啶片治疗中老年原发性高血压的效果观察[J]. 饮食保健,2018,5(32):71-72.
[12].王依繁,闫佳琳,张翼等. 复方利血平氨苯蝶啶片治疗原发性高血压有效性及安全性的Meta分析[J]. 临床药物治疗杂志,2021,19(9):28-33.
[13].Lobay D. Rauwolfia in the treatment of hypertension[J]. Integr Med (Encinitas),2015,14(3):40-46.
[14].Umemura S,Arima H,Arima S,et al. The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2019)[J]. Hypertens Res,2019,42(9):1235-1481.
[15].Unger T,Borghi C,Charchar F,et al. 2020 International Society of Hypertension global hypertension practice guidelines[J]. J Hypertens,2020,38(6):982-1004.
[16].Rabi DM,McBrien KA,Sapir-Pichhadze R,et al. Hypertension Canada’s 2020 Comprehensive Guidelines for the prevention,diagnosis,risk assessment,and treatment of hypertension in adults and children[J]. Can J Cardiol,2020,36(5):596-624.
[17].Guideline for the pharmacological treatment of hypertension in adults [Internet][J]. Geneva:World Health Organization,2021.
[18].Visseren FLJ,Mach F,Smulders YM,et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice[J]. Eur J Prev Cardiol ,2022,29(1):5-115.
[19].Wang TD,Chiang CE,Chao TH,et al. 2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension[J]. Acta Cardiol Sin,2022,38(3):225-325.
[20]. Paczkowska-Walendowska M,Sip S,Staszewski R,et al. Single-pill combination to improve hypertension treatment:pharmaceutical industry development[J]. Int J Environ Res Public Health,2022,19(7):4156.
[21].郭党社,雷新军,王燕妮. 赖诺普利氢氯噻嗪片与赖诺普利联合氢氯噻嗪片治疗原发性高血压239例对比观察[J]. 陕西医学杂志,2014,43(9):1219-1221.
[22].秦春华,谭平. 培哚普利吲达帕胺片治疗高血压患者的临床疗效及安全性分析[J]. 中国现代药物应用,2020,14(24):170-172.
[23].曲慧馨,张梅. 培哚普利吲达帕胺复方制剂对老年单纯收缩期高血压患者的降压疗效探讨[J]. 重庆医学,2014,43(25):3359-3361.
[24].Ames MK,Atkins CE,Pitt B. The renin-angiotensin-aldosterone system and its suppression[J]. J Vet Intern Med,2019,33(2):363-382.
[25].Uchiwa H,Kai H,Iwamoto Y,et al. Losartan/hydrochlorothiazide combination is safe and effective for morning hypertension in very-elderly patients[J]. Clin Exp Hypertens,2018,40(3):267-273.
[26].李渊源,龚保源,冯妲. 厄贝沙坦氢氯噻嗪辅助治疗高血压患者的效果及对血管内皮功能和机体炎症反应的影响[J]. 中国卫生工程学,2021,20(6):1029-1031.
[27].吴玲云. 缬沙坦氢氯噻嗪片治疗原发性高血压合并慢性心功能不全的疗效和安全性问题分析[J]. 吉林医学,2021,42(5):1163-1165.
[28].Laurent S. Antihypertensive drugs[J]. Pharmacol Res,2017,124:116-125.
[29].Yin G,Li Y,Xu W,et al. Chart review of patients receiving valsartan-amlodipine single-pill combination versus valsartan and amlodipine combination for blood pressure goal achievement and effects on the Hamilton anxiety rating/Hamilton depression rating scales[J]. Medicine (Baltimore),2019,98(51):e18471.
[30].Atalar E,Eskin F,Tugtekin HB,et al. A prospective noninterventional,observational study to describe the effectiveness and safety of trandolapril and verapamil single-pill combination in the management of patients with hypertension and type 2 diabetes mellitus:a harvest TR study[J]. Biomed Res Int,2020,2020:2123601.
[31].吴小英,阴彦斌,陈岩,等. 氨氯地平贝那普利片(Ⅱ)治疗原发性高血压的临床效果和依从性及经济性分析[J]. 中国医药,2020,15(4):522-525.
[32].代云. β受体阻滞剂联合ACEI治疗高血压的研究进展[J]. 临床医药文献电子杂志,2020,7(21):45.
[33].王继光. 比索洛尔氨氯地平单片复方制剂治疗高血压[J]. 中华高血压杂志,2022,30(6):514-516.
[34].Gottwald-Hostalek U,Li L,Montenegro P. Bisoprolol/amlodipine combination therapy improves blood pressure control in patients with essential hypertension following monotherapy failure[J]. Curr Med Res Opin,2016,32(10):1735-1743.
[35].Hostalek U,Czarnecka D,Koch EM. Treatment of hypertensive patients with a fixed-dose combination of bisoprolol and amlodipine:results of a cohort study with more than 10,000 patients[J]. Cardiol Ther,2015,4(2):179-190.
[36].Park SJ,Rhee SJ. Real-world effectiveness and safety of a single-pill combination of olmesartan/amlodipine/hydrochlorothiazide in Korean patients with essential hypertension (RESOLVE):a large,observational,retrospective,cohort study[J]. Adv Ther,2020,37(8):3500-3514.
[37].Calhoun DA,Lacourcière Y,Chiang YT,Glazer RD. Triple antihypertensive therapy with amlodipine,valsartan,and hydrochlorothiazide:a randomized clinical trial[J]. Hypertension,2009,54(1):32-39.
[38].Lauffenburger JC,Landon JE,Fischer MA. Effect of combination therapy on adherence among US patients initiating therapy for hypertension:a cohort study[J]. J Gen Intern Med,2017,32(6):619-625.
[39].刘超,蒋建刚,卢鹏云. 培哚普利氨氯地平片(Ⅲ)复方制剂治疗原发性高血压的临床效果、依从性及经济性分析[J]. 中国医院药学杂志,2020,40(24):2565-2569.
[40].Zhou D,Xi B,Zhao M,et al. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults:the NHANES Ⅲ linked mortality study[J]. Sci Rep ,2018,8(1):9418.
[41].Jaffe MG,Lee GA,Young JD,et al. Improved blood pressure control associated with a large-scale hypertension program[J]. JAMA,2013,310(7):699-705.
[42].胥建君,陈新云,蒋小晶,等. 成都社区抗高血压药物使用现状及血压控制率分析[J]. 四川医学,2020,41(3):239-244.
[43].Kawalec P,Holko P,Gawin M,et al. Effectiveness of fixed-dose combination therapy in hypertension:systematic review and meta-analysis[J]. Arch Med Sci,2018,14(5):1125-1136.
[44].Abdellatif AA. Role of single-pill combination therapy in optimizing blood pressure control in high-risk hypertension patients and management of treatment-related adverse events[J]. J Clin Hypertens (Greenwich),2012,14(10):718-726.
[45].Sherrill B,Halpern M,Khan S,et al. Single-pill vs free-equivalent combination therapies for hypertension:a meta-analysis of health care costs and adherence[J]. J Clin Hypertens (Greenwich),2011,13(12):898-909.

相似文献/References:

[1]杨萌萌 王淑珍 赵若寒 熊峰.原发性高血压合并舒张性心力衰竭左房容积指数与血清脑钠肽相关性研究[J].心血管病学进展,2021,(7):667.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.022]
　YANG Mengmeng,WANG Shuzhen,ZHAO Ruohan,et al.Correlation Between Left Atrial Volume Index and Serum Brain Natriuretic Peptide in Patients with Essential Hypertension Complicated with Diastolic Heart Failure[J].Advances in Cardiovascular Diseases,2021,(12):667.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.022]
[2]郭梦阳 王守富 邢冬梅.DNA甲基化与原发性高血压关系研究进展[J].心血管病学进展,2023,(7):631.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.013]
　GUO Mengyang,WANG Shoufu,XING Dongmei.Relationship Between DNA Methylation and Essential Hypertension[J].Advances in Cardiovascular Diseases,2023,(12):631.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.013]

更新日期/Last Update: 2023-02-03